nth like DNA glycosylase 1Genealiases: FAP3 · NTH1 · OCTS3 · hNTH1
Q-omics provides the consensus-scored NTHL1 profile across patient tissues and cancer cell-line models. NTHL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NTHL1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NTHL1 protein abundance shows 25,507 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where NTHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTHL1 survival associations across molecular data types. NTHL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTHL1 RNA expression–survival associations across cancer types. High NTHL1 expression shows unfavorable associations in ACC, KICH, CHOL, KIRP, DLBC and PRAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NTHL1 RNA expression.
This table summarizes NTHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NTHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTHL1 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRP, HNSC, STAD and BRCA. The COAD box plot shows higher NTHL1 RNA expression in tumor versus normal tissue (log2 FC = +1.884, t-test p < 0.001).
This table shows molecular features associated with NTHL1 in patient tissues and cancer cell lines. In patient samples, NTHL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NTHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
